Refine Results
  1. "Sarcoma Service"
Formats
  1. Meeting Abstract (240)
  2. Journal Article (223)
  3. Review (6)
  4. Book Section (4)
  5. Guidelines (3)
  6. Book Whole (1)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Sarcoma Service (480)
  2. Solid Tumor Oncology Division (480)
  3. GSK Faculty (178)
  4. Human Oncology and Pathogenesis Program (123)
  5. Surgery (105)
  6. Epidemiology and Biostatistics (74)

More Groups

People
  1. William Tap (183)
  2. Sandra D'Angelo (144)
  3. Mrinal Gounder (120)
  4. Mark Dickson (92)
  5. Ping Chi (84)
  6. Cristina Antonescu (74)

More People

Years
  1. 2021 (19)
  2. 2020 (89)
  3. 2019 (69)
  4. 2018 (75)
  5. 2017 (39)
  6. 2016 (43)

More Years

Publications
  1. Journal of Clinical Oncology (162)
  2. Annals of Oncology (34)
  3. Clinical Cancer Research (23)
  4. Journal for ImmunoTherapy of Cancer (16)
  5. Cancer Research (15)
  6. Cancer (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (169)
  2. American Association for Cancer Research (45)
  3. Oxford University Press (35)
  4. Elsevier Inc. (32)
  5. Nature Publishing Group (30)
  6. Biomed Central Ltd (21)

More Publishers

Results (480)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Avapritinib in patients with advanced gastrointestinal stromal tumors following at least three prior lines of therapy
    Journal Article

    George, S.; Jones, R. L.; Bauer, S.; Kang, Y. K.; Schöffski, P.; Eskens, F.; Mir, O.; Cassier, P. A.; Serrano, C.; Tap, W. D.; more...
    The Oncologist (2021)

    Fulltext@MSK | Save
  • Selinexor, a first in class, nuclear export inhibitor for the treatment of advanced malignant peripheral nerve sheath tumor
    Journal Article

    Al-Ezzi, E.; Gounder, M.; Watson, G.; Mazzocca, A.; D'Angelo, S. P.; Bravetti, J.; Wang, H.; Abdul Razak, A.; Vincenzi, B.
    The Oncologist (2021)

    Fulltext@MSK | Save
  • Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma
    Journal Article

    Gounder, M. M.; Merriam, P.; Ratan, R.; Patel, S. R.; Chugh, R.; Villalobos, V. M.; Thornton, M.; Van Tine, B. A.; Abdelhamid, A. H.; Whalen, J.; more...
    Cancer (2021)

    Fulltext@MSK | Save
  • The emerging role of immunotherapy for the treatment of sarcoma
    Review

    Klemen, N. D.; Kelly, C. M.; Bartlett, E. K.
    Journal of Surgical Oncology (2021)

    Fulltext@MSK | Save
  • Population pharmacokinetic analysis of pexidartinib in healthy subjects and patients with tenosynovial giant cell tumor or other solid tumors
    Journal Article

    Yin, O.; Wagner, A. J.; Kang, J.; Knebel, W.; Zahir, H.; van de Sande, M.; Tap, W. D.; Gelderblom, H.; Healey, J. H.; Shuster, D.; more...
    Journal of Clinical Pharmacology (2021)

    Fulltext@MSK | Save
  • Long-term outcomes of pexidartinib in tenosynovial giant cell tumors
    Journal Article

    Gelderblom, H.; Wagner, A. J.; Tap, W. D.; Palmerini, E.; Wainberg, Z. A.; Desai, J.; Healey, J. H.; van de Sande, M. A. J.; Bernthal, N. M.; Staals, E. L.; more...
    Cancer (2021)

    Fulltext@MSK | Save
  • Oncohistone mutations enhance chromatin remodeling and alter cell fates
    Journal Article

    Bagert, J. D.; Mitchener, M. M.; Patriotis, A. L.; Dul, B. E.; Wojcik, F.; Nacev, B. A.; Feng, L.; Allis, C. D.; Muir, T. W.
    Nature Chemical Biology (2021)

    Fulltext@MSK | Save
  • Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: Evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation
    Journal Article

    Zuco, V.; Pasquali, S.; Tortoreto, M.; Brich, S.; Percio, S.; Dagrada, G. P.; Colombo, C.; Sanfilippo, R.; Lauricella, C.; Gounder, M.; more...
    Journal of Experimental & Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling
    Journal Article

    Ceraudo, E.; Horioka, M.; Mattheisen, J. M.; Hitchman, T. D.; Moore, A. R.; Kazmi, M. A.; Chi, P.; Chen, Y.; Sakmar, T. P.; Huber, T.
    Journal of Biological Chemistry (2021)

    Fulltext@MSK | Save